Oncodesign, a provider of pharmacological evaluation services, has entered its second research collaboration agreement with Sanofi relating to several kinase targets being developed by Sanofi.  This second agreement aims to identify inhibitors of a kinase that plays a key role in tissue protection and repair. Financial details were not disclosed.   Oncodesign will use its Nanocyclix technology to design and synthesize potent new selective inhibitors. Sanofi will be responsible for the cost of th...